Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against fas‐induced apoptosis

Hayashi, Shinya; Miura, Yasushi; Nishiyama, Tomihiro; Mitani, Makoto; Tateishi, Kensuke; Sakai, Yoshitada; Hashiramoto, Akira; Kurosaka, Masahiro; Shiozawa, Shunichi; Doita, Minoru

doi:10.1002/art.22494

Cited by 74 publications

(70 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17 Human renal interstitial fibroblasts constitutively express Fas and are susceptible to Fas-induced apoptosis. 19 Hayashi et al 18 found that TNFRSF6B offers a survival benefit to synovial fibroblasts in terms of protection against cytotoxic and regulatory effects of Fas. In accordance with these findings, we also showed that TNFRSF6B could protect renal myofibroblasts against Fas-induced apoptosis (Supplementary Figure S1).…”

Section: Discussionmentioning

confidence: 99%

“…17 Anti-apoptotic effect of TNFRSF6B has been shown to decrease elimination of rheumatoid synovial fibroblasts by blocking the interaction with Fas ligand. 18 Fas is normally expressed in human renal interstitial fibroblasts 19 and we hypothesize that TNFRSF6B could involve in the renal fibrogenesis. Therefore, it prompts us to investigate whether TNFRSF6B is pathologically expressed in the kidney tissues of patients with chronic kidney disease, and to appraise whether expression of TNFRSF6B in kidneys is a newer tissue biomarker for prediction of disease progression.…”

mentioning

confidence: 85%

See 1 more Smart Citation

Expression of TNFRSF6B in kidneys is a novel predictor for progression of chronic kidney disease

Tseng

Yang

et al. 2013

Modern Pathology

View full text Add to dashboard Cite

TNFRSF6B overexpression in tumors is a novel predictor for poor prognosis in various cancers; however, whether TNFRSF6B could be expressed in kidney tissues of patients with chronic kidney disease is unknown. Current established risk factors cannot fully predict the progression of chronic kidney disease, and, therefore, it is mandatory to develop a newer marker for predicting disease progression. We conducted a prospective cohort study comprised 167 patients with chronic kidney disease undergoing renal biopsy at a tertiary hospital with median follow-up of 30.5 months. Computer-assisted quantitative immunohistochemical staining analysis of TNFRSF6B in kidney tissues, the expression of a-smooth muscle actin and percentage of fibrosis in renal interstitium, estimated glomerular filtration rate, and urinary protein excretion rate were investigated. Study endpoint was a doubling of serum creatinine and/or end-stage renal failure requiring renal replacement therapy. We found that TNFRSF6B was predominantly expressed in the tubular epithelial cells of renal cortex. The higher the expression of TNFRSF6B, the more the expression of a-smooth muscle actin and fibrosis in interstitium (Po0.001). Forty patients reaching endpoint had lower baseline estimated glomerular filtration rate and higher expression of TNFRSF6B in renal tubular epithelial cells. Multivariate Cox regression analysis showed that high expression of TNFRSF6B independently predicted the risk toward the renal endpoint with a hazard ratio of 3.46 (95% confidence interval (CI) 1.76-6.80, Po0.001) by adjusting for clinical and pathologic variables. While added to a model of estimated glomerular filtration rate, proteinuria and other conventional risk factors, TNFRSF6B further significantly improved the model predictability for progression of chronic kidney disease (area under the curve, 0.82). In conclusion, TNFRSF6B is associated with renal fibrosis and high expression of TNFRSF6B is a novel biomarker for predicting the progression of chronic kidney disease. Modern Pathology (2013) 26, 984-994;

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 85%

Expression of TNFRSF6B in kidneys is a novel predictor for progression of chronic kidney disease

Tseng

Yang

et al. 2013

Modern Pathology

View full text Add to dashboard Cite

show abstract

“…Although other mechanisms, including upregulation of inflammatory cytokines and/or interaction with other ligands, can occur as well, our evidences are consistent with literature data reporting that DcR3 can bind FasL, and may act as an inhibitor of FasL-induced cell death. 15,16,30 This is an important point considering that FasL-mediated apoptosis is the most common physiological form of cell death, and occurs during embryonic development, tissue remodeling, immune regulation and tumor regression. Abnormalities in the FasL system and the overexpression of DcR3 associated with a resistance to FasLmediated apoptosis can result in a number of human pathological conditions, including tumors.…”

Section: Discussionmentioning

confidence: 99%

Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients

et al. 2009

View full text Add to dashboard Cite

Decoy receptor 3 (DcR3), a member of the tumor necrosis factor (TNF) receptor superfamily, is known to be involved in cell survival and osteoclast (OC) formation. In this study, we show that malignant plasma cells and T lymphocytes from multiple myeloma (MM) bone disease patients, as well as Karpas 909, a human myeloma cell line, directly produce DcR3. By interacting with FasL, this molecule could inhibit OC apoptosis. In fact, the use of a neutralizing anti-DcR3 antibody induces a reduction of cell viability with a consequent increase of apoptotic cell number, the activation of caspase-8 and -3, and DNA fragmentation. Furthermore, we show that DcR3 supports OC formation in samples from MM patients through the upregulation of RANKL and TNFa by T lymphocytes and only TNFa by CD14 þ cells. In conclusion, our data provide the first evidence of the expression of DcR3 in MM, and the involvement of this molecule in supporting the survival and formation of OCs from MM bone disease patients. The production of DcR3 by T lymphocytes confers these cells a role in the pathogenesis of bone disease associated with MM.

show abstract

“…[4] DcR3 exerts pleiotropic roles as a decoy receptor by an anti-apoptotic activity and a non-decoy receptor by its direct immune-modulatory properties. Recent studies have shown that DcR3 is up-regulated and may be pathogenetically implicated in sepsis and diverse chronic inflammatory diseases.…”

Section: Discussionmentioning

confidence: 99%

“…[4] The role of DcR3 in infection has been studied in depth. [5] , had analyzed DcR3 mRNA levels in purified cell populations obtained from peripheral blood mononuclear cell (PBMC) from healthy donors by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR).…”

Section: Introductionmentioning

confidence: 99%

Rapid and Specific Diagnosis of Bacterial Sepsis in High Risk Patients

Ali¹

2017

WJPPS

View full text Add to dashboard Cite

Sepsis is a major healthcare problem worldwide, athe accurate and timely detection of sepsis remains a challenge specially in high risk This study was performed on 80 subjects (52 subjects suggestive to be bacterial sepsis patients and 28 subjects apparently healthy blood donors as a control).Peripheral venous blood was collected to be utilized for polymerase chain reaction and serum used for measurement of DCR3 by (EIA). Twenty five samples were PCR positive(48%) and 27 samples were PCR negative PCR with sensitivity, specificity, positive predictive value and negative predictive value 100,90, 88 and 100 respectively. The average DCR3 level was 10.35 fold than the control group in sepsis and We recommended that the amplification of 16s ribosomal DNA by PCR providing highly sensitive and time saving diagnostic technique and measurement of DCR3 by EIA provide a noninvasive, specific biomarker for prediction of bacterial sepsis progression and discrimination between bacterial sepsis and systemic inflammatory response syndrome.

show abstract

Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against fas‐induced apoptosis

Cited by 74 publications

References 37 publications

Expression of TNFRSF6B in kidneys is a novel predictor for progression of chronic kidney disease

Expression of TNFRSF6B in kidneys is a novel predictor for progression of chronic kidney disease

Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients

Rapid and Specific Diagnosis of Bacterial Sepsis in High Risk Patients

Contact Info

Product

Resources

About